Publicaciones en las que colabora con Antonio Naranjo Hernández (19)

2021

  1. Organisational and Clinical Approach to Osteoporosis in Rheumatology: OP-SER-Excellence Survey and Consensus

    Reumatologia Clinica, Vol. 17, Núm. 6, pp. 322-328

2020

  1. Bacteremia in systemic lupus erythematosus in patients from a Spanish registry: Risk factors, clinical and microbiological characteristics, and outcomes

    Journal of Rheumatology, Vol. 47, Núm. 2, pp. 234-240

  2. Digestive involvement in primary Sjögren's syndrome: analysis from the Sjögrenser registry

    Clinical and experimental rheumatology, Vol. 38, Núm. 4, pp. 110-115

  3. Tobacco smoking is an independent factor associated with retinal damage in systemic lupus erythematosus: a cross-sectional and retrospective study

    Rheumatology International, Vol. 40, Núm. 3, pp. 367-374

2018

  1. Variability in the prescription of biological drugs in rheumatoid arthritis in Spain: a multilevel analysis

    Rheumatology International, Vol. 38, Núm. 4, pp. 589-598

2017

  1. Fibromyalgia prevalence and associated factors in primary Sjögren's syndrome patients in a large cohort from the Spanish Society of Rheumatology registry (SJOGRENSER)

    Clinical and Experimental Rheumatology, Vol. 35, pp. 28-34

  2. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

    British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649

2016

  1. Centre-related variability in hospital admissions of patients with spondyloarthritis

    Rheumatology International, Vol. 36, Núm. 9, pp. 1301-1308

2015

  1. La enseñanza de la reumatología en la universidad. La travesía desde el aprendizaje basado en el profesor al centrado en el alumno

    Reumatologia Clinica, Vol. 11, Núm. 4, pp. 196-203

  2. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640

2013

  1. Orthopedic surgery in rheumatoid arthritis in the era of biologic therapy

    Journal of Rheumatology, Vol. 40, Núm. 11, pp. 1850-1855

2011

  1. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

    Seminars in Arthritis and Rheumatism, Vol. 41, Núm. 3, pp. 524-533

  2. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review

    Seminars in Arthritis and Rheumatism, Vol. 40, Núm. 4, pp. 330-337

2010

  1. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1751-1755

  2. Limited value of ultrasound assessment in patients with poor outcome after carpal tunnel release surgery

    Scandinavian Journal of Rheumatology, Vol. 39, Núm. 5, pp. 409-412

2009

  1. Usefulness of clinical findings, nerve conduction studies and ultrasonography to predict response to surgical release in idiopathic carpal tunnel syndrome

    Clinical and Experimental Rheumatology, Vol. 27, Núm. 5, pp. 786-793

2008

  1. Reacciones adversas relacionadas con la administración de inhibidores del TNF. Análisis de un registro de terapias biológicas

    Reumatologia Clinica, Vol. 4, Núm. 3, pp. 90-95

2004

  1. Prevelance and associated factors of anterior atlantoaxial luxation in a nation-wide sample of rheumatoid arthritis patients

    Clinical and Experimental Rheumatology, Vol. 22, Núm. 4, pp. 427-432

2003

  1. Patterns of disease modifing antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis

    Journal of Rheumatology, Vol. 30, Núm. 4, pp. 697-704